Cerenovus, part of DePuy Synthes Products, Inc.

Clinical trials sponsored by Cerenovus, part of DePuy Synthes Products, Inc., explained in plain language.

Now part of Johnson & Johnson JNJ NYSE

Medical device company focused on neurovascular care, owned by Johnson & Johnson.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Brain artery block shows promise for stopping migraines Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 1 Not yet finished but already full! 1 Completed 2

Stroke device trial pulled before it even started

Disease control Cancelled

This trial was designed to test a device called the CEREGLIDE 92 catheter, which aims to remove large blood clots from the brain in people having a severe stroke. The study planned to enroll patients with acute ischemic stroke and high disability scores. However, the trial was wi…

Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc. • Aim: Disease control

Last updated Jun 26, 2026 12:55 UTC

Cerenovus, part of DePuy Synthes Products, Inc.

Upcoming readouts

Stroke device trial pulled before it even started